P96 Serum protein N-glycosylation as a biomarker of paediatric NAFLD. (6th September 2011)

• Record Type: Journal Article
• Authors: Fitzpatrick, E; Blomme, B; Quaglia, A; Bruyne, R D; Vlierberghe, H V; Dhawan, A
• Is Part Of: Gut. Volume 60:(2011)Supplement 2
• Page Start: A45
• Page End: A45
• Publication Date: 2011-09-06
• Subjects: Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2011-300857a.96
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Introduction: Serum protein N-glycosylation has previously been shown to distinguish adult patients with simple steatosis from those with non-alcoholic steatohepatitis (NASH). The pattern of the disease in paediatric patients is distinct from adults. Aim: The aim of this study was to characterise the glycomic profile of children with varying degrees of NAFLD to identify potential biomarker profiles of disease. Method: Children with biopsy proven non-alcoholic fatty liver disease (n=51) were recruited from a tertiary paediatric hepatology unit. Liver biopsy was scored according to NAFLD activity score. Blood was taken on day of biopsy for analysis. Serum protein N-glycosylation patterns were assessed with DNA-sequencer assisted fluorophore-assisted capillary electrophoresis (DSA-FACE) and compared with histology. Results: Median age at biopsy was 13.3 years (range 4.5–17.4). 31 were male. Median BMI z-score was 1.81. 23 children scored as simple steatosis/borderline NASH and 28 as true NASH. 18 children had no/minimal fibrosis (< F2) and 33 had significant fibrosis (≥ F2). Similar to previous work in adult patients with NAFLD, peak 1 (NGA2F) was the most significantly raised N-glycan in paediatric NASH patients with peak 5 (NA2) demonstrating the greatest decrease. The logarithmically transformed ratio of peak 1 to peak 5 (Glycomarker) was −0.85 (SD 0.22) in simple steatosis/borderline NASH and −0.73 (SD 0.12) in NASH (p=0.02). The biomarker correlated well with the amount of lobular inflammation with a consistent increase with ascending grade of inflammation. There was also a trend towards significance in differentiating patients with significant fibrosis ≥ F2; −0.74 (SD 0.13) from patients with no/minimal fibrosis < F2; −0.86 (SD 0.24), (p=0.06). Glyco-analysis of immunoglobulin G (IgG) confirmed the undergalactosylation status with a significant increase in peak 1 (NGA2F; p=0.024) and a significant decrease of peak 6 (NA2F; p=0.01) on IgG. In multivariate analysis of the Glycomarker, GGT, AST and INR, only the Glycomarker displayed a significant result for distinguishing simple steatosis from NASH (p=0.019). Conclusion: In conclusion, the findings in this study are novel in that they represent the first Glycomic analysis of paediatric NAFLD. They validate findings in adults in that a Glycomarker can serve reliably as a biomarker of severity of disease in NAFLD. The same N-glycosylation alterations are observed in paediatric NASH patients when compared to an adult population and therefore the same biomarker can be used. B cells play a dominant role in the N-glycan alterations of NASH patients, both in an adult and paediatric population.